rhBMP-2 is safe and improves outcomes in open tibial fractures .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients
J Bone Joint Surg Am. 2002 Dec;84-A(12):2123-34450 patients with an open tibial fracture were randomized to receive the standard of care with either intramedullary nail fixation and routine soft-tissue management (the control group), an implant containing 0.75 mg/mL of rhBMP-2 alongside the standard care, or an implant containing 1.50 mg/mL of rhBMP-2 alongside the standard care. The rhBMP-2 implant was placed over the fracture at the time of wound closure. At 12 months, the 1.50-mg/mL rhBMP-2 group had a 44% reduction in the risk of failure, significantly fewer invasive interventions and hardware failures, faster wound-healing and significantly faster fracture healing than the control patients. .
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics